NASDAQ:OMED - Oncomed Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.29 +0.38 (+19.90 %) (As of 10/16/2018 04:00 PM ET)Previous Close$1.91Today's Range$1.90 - $2.2952-Week Range$1.74 - $5.56Volume89,300 shsAverage Volume127,300 shsMarket Capitalization$81.62 millionP/E Ratio-2.20Dividend YieldN/ABeta1.76 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California. Receive OMED News and Ratings via Email Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:OMED CUSIPN/A Webwww.oncomed.com Phone650-995-8200 Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.45 Price-To-Earnings Trailing P/E Ratio-2.20 Forward P/E Ratio-3.58 P/E GrowthN/A Sales & Book Value Annual Sales$38.15 million Price / Sales2.31 Cash FlowN/A Price / CashN/A Book Value($1.28) per share Price / Book-1.79 Profitability EPS (Most Recent Fiscal Year)($1.04) Net Income$-39,060,000.00 Net Margins-26.64% Return on EquityN/A Return on Assets-10.47% Miscellaneous Employees56 Outstanding Shares38,500,000Market Cap$81.62 million Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions What is Oncomed Pharmaceuticals' stock symbol? Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED." How were Oncomed Pharmaceuticals' earnings last quarter? Oncomed Pharmaceuticals Inc (NASDAQ:OMED) released its quarterly earnings data on Thursday, August, 2nd. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.13. The biopharmaceutical company earned $6.87 million during the quarter, compared to analysts' expectations of $7.49 million. View Oncomed Pharmaceuticals' Earnings History. When is Oncomed Pharmaceuticals' next earnings date? Oncomed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 1st 2018. View Earnings Estimates for Oncomed Pharmaceuticals. What price target have analysts set for OMED? 2 analysts have issued 12 month price objectives for Oncomed Pharmaceuticals' shares. Their forecasts range from $2.00 to $6.00. On average, they expect Oncomed Pharmaceuticals' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 74.7% from the stock's current price. View Analyst Price Targets for Oncomed Pharmaceuticals. What is the consensus analysts' recommendation for Oncomed Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncomed Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Oncomed Pharmaceuticals. Who are some of Oncomed Pharmaceuticals' key competitors? Some companies that are related to Oncomed Pharmaceuticals include Geron (GERN), Tocagen (TOCA), Seres Therapeutics (MCRB), Neptune Wellness Solutions (NEPT), Sienna Biopharmaceuticals (SNNA), Paratek Pharmaceuticals (PRTK), Unum Therapeutics (UMRX), MEI Pharma (MEIP), Innate Pharma (IPHYF), BIOFRONTERA AG/ADR (BFRA), Acer Therapeutics (ACER), Axovant Sciences (AXON), Athersys (ATHX), Aldeyra Therapeutics (ALDX) and Tyme Technologies (TYME). Who are Oncomed Pharmaceuticals' key executives? Oncomed Pharmaceuticals' management team includes the folowing people: Mr. Perry A. Karsen, Exec. Chairman (Age 63)Dr. John A. Lewicki, Pres, CEO & Director (Age 66)Dr. Austin Gurney, Chief Scientific Officer & Sr. VP (Age 54)Dr. Alicia J. Hager, Sr. VP & Gen. Counsel (Age 48)Ms. Yvonne Li, VP of Fin. & Admin. and Controller (Age 58) Who are Oncomed Pharmaceuticals' major shareholders? Oncomed Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.25%). Company insiders that own Oncomed Pharmaceuticals stock include Alicia J Hager, Jack W Lasersohn, John A Lewicki, Jonathan D Root, Paul J Hastings, Perry A Karsen, Sunil Patel, Timothy Hoey and Yvonne Li. View Institutional Ownership Trends for Oncomed Pharmaceuticals. Which institutional investors are buying Oncomed Pharmaceuticals stock? OMED stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. Company insiders that have bought Oncomed Pharmaceuticals stock in the last two years include Jack W Lasersohn and Perry A Karsen. View Insider Buying and Selling for Oncomed Pharmaceuticals. How do I buy shares of Oncomed Pharmaceuticals? Shares of OMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Oncomed Pharmaceuticals' stock price today? One share of OMED stock can currently be purchased for approximately $2.29. How big of a company is Oncomed Pharmaceuticals? Oncomed Pharmaceuticals has a market capitalization of $81.62 million and generates $38.15 million in revenue each year. The biopharmaceutical company earns $-39,060,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Oncomed Pharmaceuticals employs 56 workers across the globe. What is Oncomed Pharmaceuticals' official website? The official website for Oncomed Pharmaceuticals is http://www.oncomed.com. How can I contact Oncomed Pharmaceuticals? Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected] MarketBeat Community Rating for Oncomed Pharmaceuticals (NASDAQ OMED)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 239 (Vote Outperform)Underperform Votes: 218 (Vote Underperform)Total Votes: 457MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/16/2018 by MarketBeat.com StaffFeatured Article: How much money do you need to begin day trading?